Advertisement
Canada markets closed
  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CAD/USD

    0.7323
    +0.0000 (+0.00%)
     
  • CRUDE OIL

    83.86
    +0.29 (+0.35%)
     
  • Bitcoin CAD

    87,555.08
    -642.83 (-0.73%)
     
  • CMC Crypto 200

    1,386.53
    +3.95 (+0.29%)
     
  • GOLD FUTURES

    2,342.10
    -0.40 (-0.02%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • NASDAQ futures

    17,757.00
    +189.50 (+1.08%)
     
  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • NIKKEI 225

    37,591.22
    -37.26 (-0.10%)
     
  • CAD/EUR

    0.6823
    +0.0002 (+0.03%)
     

Chemiluminescence Immunoassay Market to Surpass US$ 10.1 Billion by 2028, Says Coherent Market Insights (CMI)

SEATTLE, Sept. 27, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global chemiluminescence immunoassay market is estimated to be valued at US$ 6.01 billion in 2021 and is expected to exhibit a CAGR of 8.0 % during the forecast period (2021-2028).

Key Trends and Analysis of the Global Chemiluminescence Immunoassay Market:

Key trends in the market include increasing number of human immunodeficiency virus disease cases and increasing number of product launches and approvals by market players.

Increasing number of cases of human immunodeficiency virus (HIV) disease is expected to drive the growth of global chemiluminescence immunoassay market. For instance, according to UNAIDS (Joint United Nations Program on HIV and AIDS), in 2020, 37.7 million people were living with HIV worldwide. 1.5 million were newly infected with HIV and almost 680,000 people died from AIDS (acquired immune deficiency syndrome)-related illnesses globally in 2020.

ADVERTISEMENT

The increasing number of product launches is expected to bolster growth of the global chemiluminescence immunoassay market. For instance, on April 17, 2020, Roche, global leader in pharmaceuticals and diagnostics, announced the launch of its Elecsys Anti-SARS-CoV-2 serology test. The Elecsys AntiSARSCoV2 Immunoassay is an in vitro test in which human serum and plasma from a blood sample are used to detect antibodies and determine the body's own immune response to SARSCoV2. The test can be used in epidemiological studies to better understand the spread of the disease and it can also be used in conjunction with molecular testing to aid in the diagnosis of patients with suspected COVID-19.

Request for Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4656

Increase in product launches by market players is expected to drive the growth of the global chemiluminescence immunoassay market. For instance, on December 18, 2020, Beckman Coulter, a leader in clinical diagnostics, announced the launch of the new Access SARSCoV2 Antigen Assay, one of the first cost-effective, high-quality, high-throughput COVID-19 assays available in the U.S. in the order of volume, workflow and flexibility are needed to fight the COVID-19 pandemic.

Key Market Takeaways:

Increasing research and development activities, rising product launches and approvals, inorganic activities such as collaborations, agreements, acquisitions, and others are expected to drive growth of the global chemiluminescence immunoassay market over the forecast period. For instance, on April 15, 2020, Accelerate Diagnostics, Inc., an in vitro diagnostics company, announced that it has entered into a commercial supply and collaboration agreement with BioCheck, Inc., a privately held San Francisco-based company focused on in vitro diagnostics. Under the terms of the agreement, Accelerate Diagnostics will distribute BioCheck MSFAST, a fully automated chemiluminescence immunoassay analyzer, along with BioCheck's SARSCoV2 tests for the detection of IgG and IgM antibodies. The agreement covers North America, Europe, and the Middle East.

Competitive Landscape:

Key players operating in the global chemiluminescence immunoassay market include DiaSorin S.p.A., Abbott Laboratories, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers, Beckman Coulter Inc., F. Hoffmann-La Roche AG, Inova Diagnostics, Inc., Maccura Biotechnology Co., Ltd., Tosoh Corporation, and Ortho Clinical Diagnostic.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4656

Market Segmentation:

  • Global Chemiluminescence Immunoassay Market, By Product Type:

    • Analyzers

      • Automated

      • Semi-automated

    • Reagents

      • Luminophore Markers

      • Enzymatic Markers

    • Consumables

  • Global Chemiluminescence Immunoassay Market, By Application :

    • Therapeutic Drug Monitoring

    • Oncology

    • Cardiology

    • Endocrinology

    • Infectious Disease

    • Autoimmune Disease

    • Others

  • Global Chemiluminescence Immunoassay Market, By End User:

    • Hospitals

    • Clinical Laboratories

    • Pharmaceutical and Biotechnology Companies

    • Others

  • Global Chemiluminescence Immunoassay Market, By Region:

    • North America

      • By Country:

        • U.S.

        • Canada

    • Latin America

      • By Country:

        • Brazil

        • Mexico

        • Argentina

        • Rest of Latin America

    • Europe

      • By Country:

        • U.K.

        • Germany

        • Italy

        • Spain

        • France

        • Russia

        • Rest of Europe

    • Asia Pacific

      • By Country

        • China

        • India

        • Japan

        • Australia

        • South Korea

        • ASEAN

        • Rest of Asia Pacific

    • Middle East

      • By Country:

        • GCC

        • Israel

        • Rest of Middle East

    • Africa

      • By Country/Region:

        • South Africa

        • Central Africa

        • North Africa

Related Market Intelligence Reports:

U.K. Drug for Abuse Testing Devices Market, by Product Type (Immunoassay Analyzers, Chromatography Instruments, Breathalyzers (Semiconductor-based Breathalyzer, Infrared (IR) Based Breathalyzer, and Fuel Cell-based Breathalyzer), Oral Fluid Testing Devices, Urine Testing Devices (Drug Testing Cup, DIP Cards, and Drug Testing Cassettes) , and Consumables (Assay Kits, Calibrators and Controls, and Others)), by Sample Type (Urine, Breathe, Saliva, Hair, and Others), and by End User (Hospitals, Federal Departments, Rehabilitation Centers, Diagnostic Laboratories, Academic Institutes and Research Centers, and Others) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

COVID-19 Detection Kits Market, by Product Type (RT-PCR Assay Kits and Immunoassay Test Strips/Cassettes), by Specimen Type (Nasopharyngeal Swab, Oropharyngeal Swab, Nasal Swab, Sputum, and Others), by End User (Hospitals, Diagnostic Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

Follow Us: LinkedIn | Twitter

CONTACT: Mr. Shah Senior Client Partner – Business Development Coherent Market Insights Phone: US: +1-206-701-6702 UK: +44-020-8133-4027 Japan: +81-050-5539-1737 India: +91-848-285-0837 Email: sales@coherentmarketinsights.com Website: https://www.coherentmarketinsights.com